24UG
Human CLIC1 mutant-Y214A
24UG の概要
| エントリーDOI | 10.2210/pdb24ug/pdb |
| 関連するPDBエントリー | 7FBQ |
| 分子名称 | Chloride intracellular channel protein 1 (2 entities in total) |
| 機能のキーワード | clic1, human chloride intracellular channel 1, mutant, glutathione s-transferase enzyme, oxidoreductase, drug discovery |
| 由来する生物種 | Homo sapiens (human) |
| タンパク質・核酸の鎖数 | 2 |
| 化学式量合計 | 53977.44 |
| 構造登録者 | |
| 主引用文献 | Kuila, S.,Ghoshal, A.,Sahoo, S.,Aathi, M.,Khan, M.A.,Panchariya, L.,Sonkar, K.S.,Khan, W.A.,Pandiramesh, J.R.,Chandele, A.,Arulandu, A. A cryptic-site ligand stabilizes a non-canonical interface and blocks membrane insertion of the chloride intracellular channel CLIC1. J.Biol.Chem., 302:113113-113113, 2026 Cited by PubMed Abstract: Human chloride intracellular channel 1 (HsCLIC1) is a dimorphic protein that exists in both soluble enzymatic and membrane-integrated ion channel forms. It is overexpressed in many cancers, yet developing specific inhibitors has been challenging, leaving CLIC proteins largely untargeted. Here, we identified a non-canonical ligand binding site on the soluble enzymatic form of HsCLIC1 and demonstrate that it is druggable with the small molecule inhibitor NSC602247. This cryptic site was discovered using multi-solvent molecular dynamics (MD) simulations followed by virtual screening and molecular docking. Using surface plasmon resonance and microscale thermophoresis, we show that NSC602247 binds to HsCLIC1 with micromolar affinity (∼6 μM) and inhibits the proliferation of HT29 colorectal cancer cells. To understand the mechanism of inhibition, we determined the crystal structure of the HsCLIC1-NSC602247 complex. Mechanistically, NSC602247 binding induces oligomerization of soluble HsCLIC1 and reduces its membrane expression, as revealed using flow cytometry. Our data clearly indicate that NSC602247 inhibits HT29 growth by sequestering the protein in a soluble state, thereby blocking its membrane translocation. These findings validate a novel cryptic site on CLIC1 and present a new mechanistic paradigm for inhibiting its pathological function by preventing membrane insertion, offering a promising strategy for targeted therapeutic development. PubMed: 42103216DOI: 10.1016/j.jbc.2026.113113 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (2.5 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






